Table 3.
Retroperitoneal sarcoma protocol normal tissue dose constraints
| Structure | Dose | Volume |
|---|---|---|
| Small bowel | V45 Gy | ≤50% |
| V55 Gy | ≤20 cm3 | |
| Max 55 Gy | Point dose | |
| Colon | V60 Gy | ≤20 cm3 |
| Max 60 Gy | Point dose | |
| Rectum | V60 Gy | ≤35% |
| V63 Gy | ≤30% | |
| Max 63 Gy | Point dose | |
| Stomach | V45 Gy | ≤100% |
| V50 Gy | ≤50% | |
| V55 Gy | ≤20 cm3 | |
| Max 55 Gy | Point dose | |
| Kidney (if 1 resected) | V20 Gy | ≤20% of retained kidney |
| Kidney (if both remain) | V18 Gy | ≤50%; mean dose < 15 Gy |
| Bladder | V60 Gy | ≤50% |
| V63 Gy | ≤25% | |
| Max 63 Gy | ||
| Liver | V25 Gy | ≤50% |
| V30 | ≤40% | |
| CTV2 Rx dose | ≤20% | |
| Spinal cord | V45 Gy | ≤95% |
| V50 Gy | ≤5% | |
| Max 50 Gy | ||
| Spinal nerves if applicable | 70.2 Gy equivalent (at 1.8 Gy/fx)∗ |
Point dose |
| Retained ureter(s) | Max 50.4 Gy | Point dose |
| Ureter to be resected | Max CTV2 Rx Dose | Point dose |
CTV, clinical target volume; GyRBE, Gray radiobiological equivalent.
∗
D1 (d1 + α/β) = D2 (d2 + α/β), where α/β = 3, D1 is the total dose, d1 is the fraction size, d2 is 1.8 GyRBE, and D2 is the tolerance dose.